Pregled bibliografske jedinice broj: 1030428
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis // Arthritis & Rheumatology, 71 (2019), 9; 1553-1570 doi:10.1002/art.40906 (recenziran, članak, znanstveni)
CROSBI ID: 1030428 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Phenotypes Determined by Cluster Analysis and
Their Survival in the Prospective European
Scleroderma Trials and Research Cohort of Patients
With Systemic Sclerosis
Autori
Sobanski, Vincent ; Giovannelli, Jonathan ; ... ; Novak, Srđan ; ... ; Martinović, Duška ; ... ; Morović- Vergles, Jadranka ; ... ; Anić, Branimir ; Barešić, Marko ; Mayer, Miroslav ; ... ; the EUSTAR Collaborators
Kolaboracija
EUSTAR Coauthors
Izvornik
Arthritis & Rheumatology (2326-5191) 71
(2019), 9;
1553-1570
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Systemic sclerosis (SSc)
Sažetak
OBJECTIVE: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained. METHODS: A total of 11, 318 patients were registered in the EUSTAR database, and 6, 927 were included in the study. Twenty-four clinical and serologic variables were used for clustering. RESULTS: Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement. CONCLUSION: Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
KBC Split,
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb,
Klinički bolnički centar Rijeka
Profili:
Branimir Anić
(autor)
Srđan Novak
(autor)
Dušanka Martinović Kaliterna
(autor)
Marko Barešić
(autor)
Jadranka Morović-Vergles
(autor)
Miroslav Mayer
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE